RIG

What Should Investors Know About Transocean (RIG) Stock?

Transocean logged a -1.5% change during today's afternoon session, and is now trading at a price of $8.13 per share. On average, analysts give it a target price of $7.62.

Transocean Ltd., together with its subsidiaries, provides offshore contract drilling services for oil and gas wells worldwide. The mid-cap company is based in Switzerland.

Make Sure to Consider the Following Before Buying Transocean:

  • RIG has a forward P/E ratio of 18.9 based on its EPS guidance of 0.43.

  • Over the last 4 years, earnings per share (EPS) have been growing at a compounded average rate of 10.4%.

  • The company has a price to earnings growth (PEG) ratio of -0.06.

  • Its Price to Book (P/B) ratio is 0.58

Transocean Has Irregular Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cashflow ($ k) YoY Growth (%)
2022-12-31 448,000 -717,000 -269,000 -173.3
2021-12-31 575,000 -208,000 367,000 175.94
2020-12-31 398,000 -265,000 133,000 382.98
2019-12-31 340,000 -387,000 -47,000 n/a

Transocean's free cash flows have a decent average of $46.0 Million over the last 4 years, but they are highly variable since their coefficient of variability is 586.7%. The compounded average growth rate over this period is -54.7%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS